With no clear benefits to researchers, a frustrating user experience, and no penalties for non-compliance, ClinicalTrials.gov is becoming increasingly irrelevant to clinical researchers and the world at large with each passing day. What does this mean for public access to research results? Is an obligation to patients putting themselves at risk in trials being breached? Why has it failed to live up to its potential?
The National Library of Medicine has a couple of powerful brands, but they’ve become conflated and compromised by poor brand management. Ultimately, their brand value is derived from the value of the MEDLINE brand, which may now be spread too thin.
Circumstantial evidence has become direct evidence — that eLife requested publication in PMC; that PMC collaborated with eLife; that PMC sought to conceal its preferential treatment; and that systems and processes at the NLM regarding PMC inclusion are unclear and open to abuse and misuse.